BidaskClub upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a hold rating to a buy rating in a report released on Friday morning.

A number of other brokerages also recently issued reports on NERV. Zacks Investment Research upgraded shares of Minerva Neurosciences from a hold rating to a buy rating and set a $12.00 price target on the stock in a report on Friday, November 9th. ValuEngine downgraded shares of Minerva Neurosciences from a strong-buy rating to a buy rating in a report on Tuesday, December 18th.

Shares of NASDAQ NERV opened at $7.59 on Friday. The firm has a market capitalization of $295.81 million, a price-to-earnings ratio of -7.03 and a beta of 1.60. Minerva Neurosciences has a 52-week low of $5.00 and a 52-week high of $12.95.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.07. On average, equities research analysts predict that Minerva Neurosciences will post -1.28 earnings per share for the current year.

In other Minerva Neurosciences news, Director William F. Doyle bought 6,000 shares of Minerva Neurosciences stock in a transaction dated Tuesday, December 11th. The shares were purchased at an average cost of $7.97 per share, for a total transaction of $47,820.00. Following the acquisition, the director now directly owns 16,611 shares in the company, valued at approximately $132,389.67. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Geoff Race sold 5,999 shares of the business’s stock in a transaction dated Monday, December 17th. The stock was sold at an average price of $7.46, for a total transaction of $44,752.54. Following the completion of the sale, the chief financial officer now owns 204,369 shares in the company, valued at $1,524,592.74. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 10,000 shares of company stock worth $77,220 and sold 16,007 shares worth $120,971. Insiders own 9.60% of the company’s stock.

Several institutional investors have recently bought and sold shares of NERV. Russell Investments Group Ltd. bought a new stake in shares of Minerva Neurosciences in the 2nd quarter worth about $925,000. Schwab Charles Investment Management Inc. increased its holdings in shares of Minerva Neurosciences by 38.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 65,567 shares of the biopharmaceutical company’s stock worth $541,000 after buying an additional 18,267 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Minerva Neurosciences by 11.2% in the 2nd quarter. BlackRock Inc. now owns 2,181,703 shares of the biopharmaceutical company’s stock worth $17,998,000 after buying an additional 219,405 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Minerva Neurosciences by 40.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 391,041 shares of the biopharmaceutical company’s stock worth $3,226,000 after buying an additional 112,461 shares during the last quarter. Finally, Renaissance Technologies LLC increased its holdings in shares of Minerva Neurosciences by 241.1% in the 2nd quarter. Renaissance Technologies LLC now owns 176,000 shares of the biopharmaceutical company’s stock worth $1,452,000 after buying an additional 124,400 shares during the last quarter. Hedge funds and other institutional investors own 75.09% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The company's lead product candidate is roluperidone, which is in Phase III clinical trial, a compound for the treatment of patients with schizophrenia.

Featured Story: Conference Calls

Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.